Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

Clearmind Medicine (Nasdaq: CMND) will host a live webinar, “Inside MEAI: Exclusive Investigator Q&A with Yale & Johns Hopkins,” on June 10, 2026, from 12:00–1:00 PM EDT.

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) will host a live webinar, “Inside MEAI: Exclusive Investigator Q&A with Yale & Johns Hopkins,” on June 10, 2026, from 12:00–1:00 PM EDT.

The event will review early clinical data from the FDA-approved Phase I/IIa multi-center trial of CMND-100, a non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder. Yale’s Dr. Anahita Bassir Nia and Johns Hopkins’ Dr. Jennifer Ellis will discuss findings, while CEO Dr. Adi Zuloff-Shani provides a clinical and corporate update. The webinar, moderated by Shannon Smadella, is free, open to the public, and requires Eventbrite registration.

Argus Jun 5 session

+36.77% close to close Open Argus

Details

News Market Reaction – CMND

On Jun 5, the day this news came out, CMND closed 36.77% above the previous close.

Data tracked by StockTitan Argus for the Jun 5 session.

Market Context

On Jun 5, the day this news came out, the stock closed 36.8% above the previous close. A strong posi...

Analysis

On Jun 5, the day this news came out, the stock closed 36.8% above the previous close. A strong positive reaction aligns with the pattern of sizeable moves around CMND-100 clinical updates, where prior trial milestones averaged about 8.54% 24h swings. Historically, both safety data and IRB decisions prompted sharp repricing. Investors should weigh this enthusiasm against financing via convertible notes and registered resale shares, which can add supply if conversions accelerate, and the inherently early-stage nature of Phase I/IIa data.

Key Figures

Webinar date: June 10, 2026 Trial phase: Phase I/IIa Participants treated: 20 participants +5 more

Webinar date

June 10, 2026

“Inside MEAI” live webinar reviewing latest CMND-100 data

Trial phase

Phase I/IIa

Ongoing multi-center CMND-100 trial for Alcohol Use Disorder

Participants treated

20 participants

Milestone reported in CMND-100 Phase I/IIa AUD trial

High dose level

160 mg

Fourth cohort dose in CMND-100 Phase I/IIa trial

Weight reduction

15–20%

Body weight reduction in prior obese mouse study with MEAI

New notes principal

$1,500,000

Convertible promissory notes under CLA agreements (June 1, 2026 6-K)

Note facility size

$10,000,000

Maximum aggregate principal under CLA securities purchase agreements

Registered resale shares

22,626,988 shares

Common shares registered on Form F-3 for note conversions

Previous Clinical trial Reports

5 past events · Latest: May 26

Same Type 5 events

1. May 26

   IRB trial advancement

   24h Move

   +14.6%

   Johns Hopkins IRB cleared CMND-100 trial to proceed to Parts B and C.

2. May 12

   Enrollment milestone

   24h Move

   +3.8%

   Reported 20 participants treated in ongoing Phase I/IIa AUD trial.

3. May 11

   Prior MEAI webinar

   24h Move

   -5.6%

   Announced earlier “Inside MEAI” webinar on latest CMND-100 data.

4. Apr 20

   Top-line safety data

   24h Move

   +58.4%

   CMND-100 met primary safety and tolerability endpoint in AUD trial.

5. Apr 15

   DSMB recommendation

   24h Move

   -28.6%

   DSMB issued positive recommendation to continue CMND-100 trial at higher dose.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase i/iia, alcohol use disorder (aud), non-hallucinogenic, neuroplastogen-derived therapeutics, +1 more

5 terms

phase i/iia medical

"ongoing FDA-approved Phase I/IIa multi-center trial evaluating CMND-100"

An early-stage clinical trial program that combines Phase I (primarily testing safety and finding a tolerable dose) with Phase IIa (initial checks for whether the drug shows signs of working in patients). Think of it as trying a new product with a small group to confirm it’s safe and gives early benefits before a larger rollout. For investors, these studies are major risk/reward checkpoints: positive results can boost value, while failures are common and costly.

alcohol use disorder (aud) medical

"for the treatment of Alcohol Use Disorder (AUD). Featured Speakers:"

A chronic medical condition in which a person repeatedly drinks alcohol in a way that they cannot control, continuing despite harm to their health, work or relationships; it ranges from risky drinking to severe dependence. Investors should care because AUD drives demand for treatments, public health spending, workplace productivity losses and regulatory attention—similar to how a persistent mechanical problem increases repair and operating costs, it creates long-term market and policy implications for healthcare, insurers and employers.

non-hallucinogenic medical

"novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics"

A non-hallucinogenic substance is one that does not produce hallucinations or significant distortions of perception, mood, or thought; think of a medicine that relieves symptoms without causing vivid sensory experiences or altered reality. For investors, non-hallucinogenic status matters because it can mean fewer safety concerns, simpler regulatory approval, broader patient acceptance, and potentially lower liability and marketing barriers, which affect commercial viability and risk.

neuroplastogen-derived therapeutics medical

"second generation, neuroplastogen-derived therapeutics to solve major under-treated"

Neuroplastogen-derived therapeutics are drugs or biological treatments developed from compounds that promote neuroplasticity — the brain’s ability to rewire and form new connections after injury or in response to learning. For investors, they matter because these therapies target underlying brain repair mechanisms rather than only masking symptoms, offering the potential for durable benefits in conditions like depression, stroke recovery, or neurodegeneration; if effective, they can create large, high-value markets similar to replacing a faulty bridge with a stronger one.

fda-approved regulatory

"latest clinical data from the Company’s ongoing FDA-approved Phase I/IIa multi-center trial"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar

Register now for free and join on June 10, 2026

Vancouver, Canada, June 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced it will host a live webinar titled 
“Inside MEAI: Exclusive Investigator Q&A with Yale & Johns Hopkins on Wednesday, June 10, 2026, from 12:00–1:00 PM EDT (9:00–10:00 AM PDT).

Interested participants are invited to register and secure their spot in this exclusive session.

The webinar will provide an in-depth review of the latest clinical data from the Company’s ongoing FDA-approved Phase I/IIa multi-center trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

Featured Speakers:

Dr. Anahita Bassir Nia, MD- Assistant Professor of Psychiatry, Yale School of Medicine. Leads clinical trials on psychedelics and novel compounds for AUD, depression, and PTSD.

Dr. Jennifer Ellis, Ph.D.- Assistant Professor and licensed clinical psychologist, Johns Hopkins Medicine. Principal investigator at the Johns Hopkins trial site, focused on novel therapeutics for substance use disorders.

Dr. Adi Zuloff-Shani, Ph.D.- CEO of Clearmind Medicine, will provide a clinical development and corporate update.

Host & Moderator: The webinar will be moderated by Shannon Smadella, MBA, Co-Executive Director of World Psychedelics Day, former board member of MAPS Canada, and Special Advisor to Clearmind Medicine.

The event is open to the public and will include a live Q&A session. Registration is available via Eventbrite.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its belief in MEAI’s potential as a transformative, non-hallucinogenic treatment option for Alcohol Use Disorder.. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the Clearmind Medicine (CMND) “Inside MEAI” webinar on June 10, 2026?

The “Inside MEAI” webinar is a live online event reviewing early clinical data from Clearmind’s CMND-100 trial for Alcohol Use Disorder. It runs June 10, 2026, 12:00–1:00 PM EDT, featuring Yale and Johns Hopkins investigators.

Which clinical trial will Clearmind Medicine (CMND) discuss in the Inside MEAI webinar?

The webinar will cover Clearmind’s ongoing FDA-approved Phase I/IIa multi-center trial of CMND-100 for Alcohol Use Disorder. According to Clearmind, investigators will share the latest clinical data and answer audience questions live.

Who are the key speakers at Clearmind Medicine’s Inside MEAI webinar for CMND-100?

Speakers include Dr. Anahita Bassir Nia from Yale and Dr. Jennifer Ellis from Johns Hopkins, both leading CMND-100 trial work. According to Clearmind, CEO Dr. Adi Zuloff-Shani will also present development and corporate updates.

How can investors register for Clearmind Medicine’s June 10, 2026 CMND-100 webinar?

Registration for the Inside MEAI webinar is available free through Eventbrite. According to Clearmind, interested participants must reserve a spot in advance to join the live one-hour online session and Q&A.

What is CMND-100 in Clearmind Medicine’s clinical program for Alcohol Use Disorder?

CMND-100 is Clearmind’s proprietary non-hallucinogenic MEAI-based oral drug candidate being tested for Alcohol Use Disorder. It is currently evaluated in an FDA-approved Phase I/IIa multi-center trial discussed in the Inside MEAI webinar.

Who will moderate the Clearmind Medicine Inside MEAI webinar on CMND-100?

The webinar will be moderated by Shannon Smadella, Co-Executive Director of World Psychedelics Day and Special Advisor to Clearmind. According to Clearmind, she will host the discussion and manage the live Q&A segment.